A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Recruiting · NCT07325136 · Interventional (participants receive a specific treatment) · Lead sponsor: Bristol-Myers Squibb
View the official record on ClinicalTrials.gov →Interventions studied
BMS-986525Pumitamig
What this trial is about
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC).
- Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
- In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.
Exclusion criteria
- Participants must not have any untreated CNS metastases.
- Participants must not have an active, known or suspected autoimmune disease.
- Participants must not have had a prior organ or tissue allograft.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where it is running
13 locations listed across 5 US states.
- Karmanos Cancer Institute - Detroit, Michigan, United States
- Local Institution - 0026 - Buffalo, New York, United States
- Duke Cancer Institute - Durham, North Carolina, United States
- University Hospitals Cleveland Medical Center - Cleveland, Ohio, United States
- SCRI Oncology Partners - Nashville, Tennessee, United States
- Centrul de Oncologie Sf. Nectarie SRL - Craiova, Romania
- Hospital Universitario 12 de Octubre - Madrid, Spain
- Local Institution - 0029 - Beijing, Beijing Municipality, China
- Istituto Clinico Humanitas - Rozzano, Milano, Italy
- Local Institution - 0020 - Hirakata, Osaka, Japan
- Local Institution - 0028 - Shanghai Shi, Shanghai Municipality, China
- Oncohelp Medical Center - Timișoara, Timiș County, Romania
- Local Institution - 0018 - Chuo-ku, Tokyo, Japan